carvedilol has been researched along with Cardiomyopathy, Hypertrophic in 8 studies
Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We identified that carvedilol, a β-blocker not commonly used in HCM, suppresses contractile function and arrhythmia by inhibiting RyR2 (ryanodine receptor type 2)." | 8.31 | Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol. ( Ashley, EA; Bernstein, D; Huang, Y; Kawana, M; Kirillova, A; Lane, KV; Parikh, VN; Perez, MV; Pruitt, BL; Seo, K; Wang, Q; Wheeler, MT; Wu, JC; Yadav, S; Yamamoto, Y, 2023) |
| "We identified that carvedilol, a β-blocker not commonly used in HCM, suppresses contractile function and arrhythmia by inhibiting RyR2 (ryanodine receptor type 2)." | 4.31 | Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol. ( Ashley, EA; Bernstein, D; Huang, Y; Kawana, M; Kirillova, A; Lane, KV; Parikh, VN; Perez, MV; Pruitt, BL; Seo, K; Wang, Q; Wheeler, MT; Wu, JC; Yadav, S; Yamamoto, Y, 2023) |
| "Carvedilol (Coreg/Kredex) is an unselective vasodilating beta-blocker with potent antioxidant activity used in the treatment of hypertension, angina, and congestive heart failure." | 3.70 | Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. ( Barone, FC; Campbell, WG; Feuerstein, GZ; Nelson, AH, 1998) |
| "Beta-blockers are used to treat cats with hypertrophic obstructive cardiomyopathy (HOCM)." | 1.51 | Left ventricular geometric characteristics predict response to carvedilol in cats with asymptomatic hypertrophic obstructive cardiomyopathy caused by systolic anterior motion of the mitral valve. ( Koyama, H; Matsumoto, H; Mochizuki, Y; Saito, T; Suzuki, R; Teshima, T; Yasumura, Y, 2019) |
| "Hypertrophic cardiomyopathy is a complex and relatively common genetic disorder characterized by left ventricular (LV) hypertrophy, usually associated with a nondilated and hyperdynamic chamber with heterogeneous phenotypic expression and clinical course." | 1.39 | Two different cardiomyopathies in a single patient : hypertrophic cardiomyopathy and left ventricular noncompaction. ( Mutlu, B; Ozben, B; Sunbul, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seo, K | 1 |
| Yamamoto, Y | 1 |
| Kirillova, A | 1 |
| Kawana, M | 1 |
| Yadav, S | 1 |
| Huang, Y | 1 |
| Wang, Q | 1 |
| Lane, KV | 1 |
| Pruitt, BL | 1 |
| Perez, MV | 1 |
| Bernstein, D | 1 |
| Wu, JC | 1 |
| Wheeler, MT | 1 |
| Parikh, VN | 1 |
| Ashley, EA | 1 |
| Kadoya, T | 1 |
| Sakakibara, A | 1 |
| Kitayama, K | 1 |
| Yamada, Y | 1 |
| Higuchi, S | 1 |
| Kawakita, R | 1 |
| Kawasaki, Y | 1 |
| Fujino, M | 1 |
| Murakami, Y | 1 |
| Shimura, M | 1 |
| Murayama, K | 1 |
| Ohtake, A | 1 |
| Okazaki, Y | 1 |
| Koga, Y | 1 |
| Yorifuji, T | 1 |
| Suzuki, R | 2 |
| Mochizuki, Y | 2 |
| Yuchi, Y | 1 |
| Yasumura, Y | 2 |
| Saito, T | 2 |
| Teshima, T | 2 |
| Matsumoto, H | 2 |
| Koyama, H | 2 |
| Hori, Y | 1 |
| Fujimoto, E | 1 |
| Nishikawa, Y | 1 |
| Nakamura, T | 1 |
| Shimada, YJ | 1 |
| Sato, K | 1 |
| Hanon, S | 1 |
| Schweitzer, P | 1 |
| Sunbul, M | 1 |
| Ozben, B | 1 |
| Mutlu, B | 1 |
| Barone, FC | 1 |
| Campbell, WG | 1 |
| Nelson, AH | 1 |
| Feuerstein, GZ | 1 |
1 trial available for carvedilol and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Assessment of myocardial function in obstructive hypertrophic cardiomyopathy cats with and without response to medical treatment by carvedilol.
Topics: Animals; Cardiomyopathy, Hypertrophic; Carvedilol; Cat Diseases; Cats; Heart; Observer Variation | 2019 |
7 other studies available for carvedilol and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Carvedilol | 2023 |
Successful treatment of infantile-onset ACAD9-related cardiomyopathy with a combination of sodium pyruvate, beta-blocker, and coenzyme Q10.
Topics: Acidosis; Acyl-CoA Dehydrogenase; Acyl-CoA Dehydrogenases; Adrenergic beta-Antagonists; Amino Acid M | 2019 |
Left ventricular outflow tract pressure gradient changes after carvedilol-disopyramide cotherapy in a cat with hypertrophic obstructive cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Cardiomyopathy, Hypertrophic; Carvedilol; Cat Diseases; Cats; | 2020 |
Left ventricular geometric characteristics predict response to carvedilol in cats with asymptomatic hypertrophic obstructive cardiomyopathy caused by systolic anterior motion of the mitral valve.
Topics: Adrenergic beta-Antagonists; Animals; Cardiomyopathy, Hypertrophic; Carvedilol; Cat Diseases; Cats; | 2019 |
Termination of recurrent ventricular tachycardia by continuous positive airway pressure ventilation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, H | 2009 |
Two different cardiomyopathies in a single patient : hypertrophic cardiomyopathy and left ventricular noncompaction.
Topics: Adrenergic beta-Antagonists; Adult; Anticoagulants; Carbazoles; Cardiomyopathy, Hypertrophic; Carved | 2013 |
Carvedilol prevents severe hypertensive cardiomyopathy and remodeling.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Blood Pressure; Body Weight; Carbazoles; | 1998 |